Skip to main content
SpringerLink
Log in

The Safety of Antimalarial Drugs in Pregnancy

  • Review Articles
  • Drug Experience
  • Published:
Drug Safety Aims and scope Submit manuscript

Summary

Alternative drugs to chloroquine are required to prevent the deleterious effects of malaria in pregnancy. Fear of potential toxicity has limited antimalarial drug use in pregnancy. Animal toxicity studies have documented teratogenicity when antimalarials are administered at high dosages. Excepting the tetracyclines, there is no evidence to suggest that, at standard dosages, any of the antimalarial drugs are teratogenic. Primaquine is not recommended because of the potential risk of haemolytic effects in the fetus. Rates of spontaneous abortion and birth defects were comparable in pregnant women taking mefloquine, compared with chloroquine-proguanil, or pyrimethamine-sulfadoxine prophylaxis, in the first trimester of pregnancy. Standard doses of quinine do not increase the risk of abortion or preterm delivery. Therapeutic mefloquine does not provoke hypoglycaemia. There is no evidence in the literature to support the hypothetical risk of kernicterus in the newborn, following exposure to antimalarial drugs containing sulphonamides or sulphones prior to delivery. Documentation of the safety of doxycycline, halofantrine, and the artemisinin derivatives in the treatment of malaria in pregnant women is currently limited.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. McGregor IA, Wilson ME, Billewicz WZ, et al. Malaria infection of the placenta in The Gambia, west Africa: its incidence and relationship to stillbirth, birthweight, and placental weight. Trans R Soc Trop Med Hyg 1983; 77: 232–44

    Article  PubMed  CAS  Google Scholar 

  2. Gilles HM, Lawson JB, Sibelas M, et al. Malaria, anaemia and pregnancy. Ann Trop Med Parasitol 1969; 63: 254–63

    Google Scholar 

  3. Brabin BJ. The risks and severity of malaria in pregnant women. Applied Field Research in Malaria Reports, No. 1. UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR), Geneva, 1991

    Google Scholar 

  4. Nathwani D, Currie PF, Douglas JG, et al. Plasmodium falciparum malaria in pregnancy: a review. Br J Obstet Gynaecol 1992; 99: 118–21

    Article  PubMed  CAS  Google Scholar 

  5. World Health Organization. Practical chemotherapy of malaria. Report of a WHO scientific group. 1990 Technical Report Series, No. 805

  6. World Health Organization. International travel and health. Geneva: World Health Organization, 1995

    Google Scholar 

  7. World Health Organization. Antimalarial drug policies: data requirements, treatment of uncomplicated malaria and management of malaria in pregnancy. Geneva: World Health Organization, 1994 Report no.: WHO/MAL/94.1070

  8. Garner P, Brabin B. A review of randomized controlled trials of routine antimalarial drug prophylaxis during pregnancy in endemic malarious areas. Bull World Health Organ 1994; 72: 89–99

    PubMed  CAS  Google Scholar 

  9. Briggs GC, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation. 2nd ed. Baltimore: Williams and Wilkins, 1986: 537–53

    Google Scholar 

  10. Reynolds J. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989

    Google Scholar 

  11. Looareesuwan S, Phillips RE, White NJ, et al. Quinine and severe falciparum in late pregnancy. Lancet 1985; 2: 4–8

    Article  PubMed  CAS  Google Scholar 

  12. Davis TM, Suputtamongkol Y, Spencer JL, et al. Glucose turnover in pregnant women with acute malaria. Clin Sci (Colch) 1994; 86: 83–90

    CAS  Google Scholar 

  13. Phillips RE, Looareesuwan S, White NJ, et al. Quinine pharmacokinetics and toxicity in pregnant and lactating women with falciparum malaria. Br J Clin Pharmacol 1986; 21: 677–83

    Article  PubMed  CAS  Google Scholar 

  14. Dyban AP. Embryotoxic and teratogenic activity of certain antimalarial drugs [unpublished document]. World Health Organization, 1967

  15. Shao B, Zhan C, Ha S, et al. The embryotoxicity of chloroquine and pyrimethamine in rats. Chi Sheng Chung Hsueh Yu Chi Sheng Chung Ping Tsa Chih 1983; 1: 134–37

    PubMed  CAS  Google Scholar 

  16. Linquist JG, Ullberg S. The melanin affinity of chloroquine and chlorpromazine studied by whole body autoradiography. Acta Pharmacol 1972; 31 Suppl. 2: 1–31

    Google Scholar 

  17. Okanlawon AO, Ejiwunmi AB, Dada MO, et al. Morphometric analysis of the effect of chloroquine on rat foetal lung maturation. East Afr Med J 1993; 70: 98–100

    PubMed  CAS  Google Scholar 

  18. Hart W, Naunton RF. The ototoxicity of chloroquine phosphate. Arch Otolaryngol Head Neck Surg 1964; 80: 407–12

    Article  CAS  Google Scholar 

  19. Lindsay J. Profound childhood deafness. Inner ear pathology. Ann Otol Rhinol Laryngol 1973; 82 Suppl. 5: 11–21

    Google Scholar 

  20. Parke AL. Antimalarial drugs, pregnancy and lactation. Lupus 1993; 2 Suppl. 1: S21–3

    Google Scholar 

  21. Parke A. Antimalarial drugs and pregnancy. Am J Med 1988; 85 Suppl. 4A: 30–3

    Article  PubMed  CAS  Google Scholar 

  22. Levy M, Buskila D, Gladman DD, et al. Pregnancy outcome following first trimester exposure to chloroquine. Am J Perinatol 1991; 8: 174–8

    Article  PubMed  CAS  Google Scholar 

  23. Petri M. Systemic lupus erythematosus and pregnancy. Rheum Dis Clin North Am 1994; 20: 87–118

    PubMed  CAS  Google Scholar 

  24. Wolfe M, Cordero J. Safety of chloroquine in chemosuppression of malaria during pregnancy. BMJ 1985; 290: 1466

    Article  PubMed  CAS  Google Scholar 

  25. Phillips-Howard PA, Steffen R, Kerr L, et al. Safety of mefloquine and other antimalarial agents in the first trimester of pregnancy. Bull World Health Organ. In press

  26. Heinonen OP, Slone D, Shapiro S. Birth defects and drugs in pregnancy. Littleton (MA): Publishing Sciences Group, Inc., 1977

    Google Scholar 

  27. Steketee RW, Wirima JJ. Malaria prevention in pregnancy: the effects of treatment and chemoprophylaxis on placental malaria infection, low birth weight, and fetal, infant, and child survival. United States Agency for International Development Africa Regional Project (698–0421), US Department of Health and Human Services, 1994

  28. Cot M, Roisin A, Barro D, et al. Effect of chloroquine chemoprophylaxis during pregnancy on birth weight: results of a randomized trial. Am J Trop Med Hyg 1992; 46: 21–7

    PubMed  CAS  Google Scholar 

  29. McDermott JM, Heymann DL, Wirima JJ, et al. Efficacy of chemoprophylaxis in preventing Plasmodium falciparum parasitaemia and placental infection in pregnant women in Malawi. Trans R Soc Trop Med Hygiene 1988; 82: 520–3

    Article  CAS  Google Scholar 

  30. Heymann DL. Khoromana CO, Wirima JJ, et al. Comparative efficacy of alternative primary therapies for Plasmodium falciparum infections in Malawi. Trans R Soc Trop Med Hyg 1987; 81: 722–4

    Article  PubMed  CAS  Google Scholar 

  31. Steketee RW, Brandling-Bennett AD, Kaseje DCO, et al. In vivo response of Plasmodium falciparum malaria to chloroquine in pregnant and non pregnant women in Siaya District, Kenya. Bull World Health Organ 1987; 65: 885–90

    PubMed  CAS  Google Scholar 

  32. Martin GE, Nwake CC. Administration de la dose unique mensuelle de 600 mg de chloroquine base dans le controle du paludisme chez les femmes encientes (OCEAC). Bull Liaison Documentation 1982; 53: 41–7

    Google Scholar 

  33. Soares R, Paulini E, Pereira JP, et al. Concentration and elimination of chloroquine by the placental circulation and the milk in patients receiving chloroquinized salt. Rev Bras Malariol Doencas Trop 1957; 9: 19–27

    Google Scholar 

  34. Walter Reed Army Institute for Research. Appendix E. Mefloquine. Background information. New drug application to the US Food and Drug Administration [unpublished]. Washington: Walter Reed Army Institute of Research, 1986

    Google Scholar 

  35. Balocco R, Bonati M. Mefloquine prophylaxis against malaria for female travellers of childbearing age. Lancet 1992; 340: 309–10

    Article  PubMed  CAS  Google Scholar 

  36. Clyde DF. Clinical problems associated with the use of primaquine as a tissue schizontocidal and gametocytocidal drug. Bull World Health Organ 1981; 59: 391–5

    PubMed  CAS  Google Scholar 

  37. Prins HK, Oort M, Loos JA, et al. Congenital non-spherocytic haemolytic anemia, associated with glutathione deficiency of the erythrocytes. Blood 1966; 27: 145

    PubMed  CAS  Google Scholar 

  38. Cutting W. Antifertility effects of biguanides. Antibiotics and chemotherapy 1962; XII(12): 671–5

    Google Scholar 

  39. Chebotar NA. Embryonic and teratogenic action of proguanil, chlorproguanil, and cycloguanil on albino mice. Bull Exp Biol Med 1974; 77: 56–7

    CAS  Google Scholar 

  40. Wangboonskul J, White NJ, Nosten F, et al. Single dose pharmacokinetics of proguanil and its metabolites in pregnancy. Eur J Clin Pharmacol 1993; 44: 247–51

    Article  PubMed  CAS  Google Scholar 

  41. Thiersch JB. Effects of certain 2,4-diaminopyrimidine antagonist of folic acid on pregnancy and rat fetus. Proc Soc Exp Biol 1954; 87: 571–7

    PubMed  CAS  Google Scholar 

  42. Krahe M. Utersuchungen uber die teratogen Wirkung von medikamenten zur behandling der toxoplasmose wahrend der Schwangerschaft [in German]. Arch Gynakol 1965; 202: 104–9

    Article  PubMed  CAS  Google Scholar 

  43. Hengst P. Untersuchungen zur Teratogenität des Daraprim (Pyrimethamine) beim Menschen. Zentralbl Gynakol 1972; 94: 551–5

    PubMed  CAS  Google Scholar 

  44. Morely D, Woodland M, Cuthbertson WFJ. Controlled trial of pyrimethamine in pregnant women. BMJ 1964; 1: 667–8

    Article  Google Scholar 

  45. Fleming A, Ghatoura GBS, Harrison KA. The prevention of megaloblastic anaemia in pregnancy. Niger J Obstet Gynaecol 1968; 75: 425–32

    CAS  Google Scholar 

  46. Nahlen BL, Akintunde A, Alakija T, et al. Lack of efficacy of pyrimethamine prophylaxis in pregnant Nigerian women. Lancet 1982; 2: 830–3

    Google Scholar 

  47. Harpey J-P, Darbois Y, Lefebvre G. Teratogenicity of pyrimethamine. Lancet 1983; 2: 399

    Article  PubMed  CAS  Google Scholar 

  48. Bertazzoli C, Chieli T, Grandi M. Absence of tooth malformation in offspring of rats treated with long-acting sulphonamide. Experientia 1965; 21: 151–2

    Article  PubMed  CAS  Google Scholar 

  49. Bohni E, Fust B, Rieder J. Comparative toxicological, chemotherapeutic and pharmacokinetic studies with sulfamethoxine and other sulphonamides in animals and man. Chemotherapy 1969; 14: 195–226

    Article  PubMed  CAS  Google Scholar 

  50. Kato T, Kitagawa S. Production of congenital abnormalities in fetuses of rats and mice with various sulfonamides. Congenital Anomalies 1973; 13: 7–13

    Google Scholar 

  51. Saxen L. Association between clefts and drugs taken during pregnancy. Int J Epidemiol 1975; 4: 37–44

    Article  PubMed  CAS  Google Scholar 

  52. Nelson MM, Forfar JO. Association between drugs administered in pregnancy and congenital abnormalities. BMJ 1971: 5748; 523–7

    Article  Google Scholar 

  53. Baskin CG, Law S, Wenger NK, et al. Sulfadiazine rheumatic fever prophylaxis during pregnancy: does it increase the risk of kernicterus in the newborn? Cardiology 1980; 65: 222–5

    Article  PubMed  CAS  Google Scholar 

  54. Thornton YS, Bowe ET. Neonatal hyperbilirubinemia after treatment of maternal leprosy. South Med J 1989; 82: 668

    Article  PubMed  CAS  Google Scholar 

  55. Fraser PJ. Effects of pyrimethamine and sulpormethoxine at a 1:20 mixture of pyrimethamine and sulfamethoxine in pregnant animals [unpublished document]. Beckenham: Wellcome Research Labs, 1969

    Google Scholar 

  56. Barbosa JC, Ferriera I. Sulfadoxine-pyrimethamine (Fansidar) in pregnant women with toxoplasma antibody titres. In: Siegenthaler W, Luthy R, editors. Current chemotherapy. Vol. I. American Society of Microbiology, 1978: 134–5

    Google Scholar 

  57. Cohlan SQ, Bevelander G, Tiamsic T. Growth inhibition of prematures receiving tetracycline. Am J Dis Child 1963; 105: 453–61

    Google Scholar 

  58. Krejci L. Eye changes due to systemic use of tetracyclines in pregnancy. Animal trials. Ophthalmic Res 1980; 12: 73–7

    Article  CAS  Google Scholar 

  59. Westland MM. Effects of tetracycline on chromosomes cultured from human lymphocytes. J Am Med Worn Assoc 1967; 22: 719

    CAS  Google Scholar 

  60. Charles D, Obst D. Placental transmission of antibiotics. J Obstet Gynaecol 1954; 61: 750–7

    CAS  Google Scholar 

  61. Seeliger RPH, Ronde G. Die Wirkung von Tetracyclingaben auf das kindliche Gebiss bei Listeriosebehandlung von Schwangeren. Geburtshilfe Frauenheilkd 1968; 28: 209

    PubMed  CAS  Google Scholar 

  62. Carter MP, Wilson F. Tetracycline and congenital limb abnormality. BMJ 1962; 2: 407–8

    Article  Google Scholar 

  63. Corcoran R, Castles JM. Tetracycline for acne vulgaris and possible teratogenesis. BMJ 1977; 2: 807–8

    Article  PubMed  CAS  Google Scholar 

  64. Krejci L, Brettschneider I. Congenital cataract due to tetracycline. Ophthalmic Paediatr Genet 1983; 3: 59–60

    Article  Google Scholar 

  65. Kutscher AH, Zagarelli EV, Tovell MMM, et al. Discolouration of teeth induced by tetracycline. JAMA 1963; 184: 586

    Article  PubMed  CAS  Google Scholar 

  66. Seo ML, Yamatodani A, Mizutani A, et al. Short-term, preweaning treatment with tetracycline affects physical development and behavior in rats. Neurotoxicology 1993; 14: 65–75

    PubMed  CAS  Google Scholar 

  67. Bastianini L, Felisati D. Studi sulla tossicita gravidica e fetale dell α-6-deossi-5-ossitetraciclina (doxiciclina) nei topo e nel coniglio [multilingual; non-English]. Antibiotica 1970; 8: 161–78

    PubMed  CAS  Google Scholar 

  68. Bocker R, Estler CJ, Muller S, et al. Comparative evaluation of the effects of tetracycline, rolitetracycline and doxycycline on some blood parameters related to liver function. Arzneimittel Forschung 1982; 32: 237–41

    PubMed  CAS  Google Scholar 

  69. Schuster BG, Canfield CJ. Preclinical studies with halofantrine In: Warhurst DC, Schofield CJ, editors. Halofantrine in the treatment of multidrug resistant malaria. Cambridge: Elsevier, 1989: 3–13

    Google Scholar 

  70. Yang Q-C. The antimalarial and toxic effects of artesunate on animal models. J Tradit Chin Med 1982; 22: 99–103

    Google Scholar 

  71. Hein TT, White NJ. Qinghaosu. Lancet 1993; 341: 603–8.

    Article  Google Scholar 

  72. China Cooperative Research Group on Qinghaosu and its derivatives as antimalarials. J Trad Chin Med 1982; 2: 1–50

    Google Scholar 

  73. Wang T-Y. Therapeutic effectiveness and toxic side-effects of artemisinin and artemether for their treatment of malaria patients in pregnancy. J Trad Chin Med 1989; 9: 28–30

    CAS  Google Scholar 

  74. Li Guo-Qiao, editor. Clinical trials on qinghaosu and its derivatives, Vol 1. Guangzhou College of Traditional Chinese Medicine, Sanya Tropical Medicine Institute, China, 1990

    Google Scholar 

  75. Guo-Qiao L, Xing-Bo G, Lin-Chun F, et al. Clinical trials of artemisinin and its derivatives in the treatment of malaria. Trans R Soc Trop Med Hyg 1994; 88 Suppl. 1: 5–6

    Google Scholar 

  76. White NJ, Looareesuwan S, Warrell DA, et al. A quinine loading dose in cerebral malaria. Am J Trop Med Hyg 1983; 32: 1–5

    PubMed  CAS  Google Scholar 

  77. Kline J, Stein Z, Susser M. Conception to birth: epidemiology of prenatal development. Monographs in epidemiology and biostatistics. Vol. 14. New York: Oxford University Press, 1990

    Google Scholar 

  78. Nosten F, ter Kuile F, Maelankiri L, et al. Mefloquine prophylaxis prevents malaria during pregnancy: a double-blind, placebo-controlled study. J Infect Dis 1994; 169: 595–603

    Article  PubMed  CAS  Google Scholar 

  79. Collignon P, Hehir J, Mitchell D. Successful treatment of falciparum malaria in pregnancy with mefloquine [letter]. Lancet 1989; 1: 967

    Article  PubMed  CAS  Google Scholar 

  80. Watkins WM, Brandling-Bennett AD, Nevill CG, et al. Chlorproguanil/dapsone for the treatment of non severe Plasmodium falciparum infection in Kenya: a pilot study. Trans R Soc Trop Med Hyg 1988; 82: 398–403

    Article  PubMed  CAS  Google Scholar 

  81. Harinasuta T, Bunnag D, Karbwang J, et al. A clinical trial of mefloquine on multidrug resistant falciparum malaria in pregnant women in Thailand. Bull Soc Francaise Parasitol 1990; 8: 429

    Google Scholar 

  82. Dorangeon PH, Marx-Chemla C, Quereux C, et al. Les risques de l’association pyrimethamine-sulfadoxine dans le traitement antenatal de la toxoplasmose [in French]. J Gynecol Obstet Biol Reprod (Paris) 1992; 21: 549–56

    CAS  Google Scholar 

  83. Maurus JN. Hansons disease in pregnancy. Obstet Gynaecol 1978; 2: 22–5

    Google Scholar 

  84. Miller K, Lobel HO, Satraile RF, et al. Severe cutaneous reactions among American travellers using pyrimethamine-sulfadoxine (Fansidar) for malaria prophylaxis. Am J Trop Med Hyg 1986; 35: 451–8

    PubMed  CAS  Google Scholar 

  85. Greenwood B, Greenwood AM, Snow RW. The effects of malaria chemoprophylaxis given by traditional birth attendants on the course and outcome of pregnancy. Trans R Soc Trop Med Hyg 1989; 83: 589–94

    Article  PubMed  CAS  Google Scholar 

  86. Greenwood AM, Menendez C, Todd J, et al. The distribution of birth weights in Gambian women who received malaria chemoprophylaxis during their first pregnancy and in control women. Trans R Soc Trop Med Hyg 1994; 88: 311–2

    Article  PubMed  CAS  Google Scholar 

  87. Menendez C, Todd J, Alonso PL, et al. Malaria chemoprophylaxis, infection of the placenta and birth weight in Gambian primigravidae. J Trop Med Hyg 1994; 97: 244–8

    PubMed  CAS  Google Scholar 

  88. Sowunmi A, Akindele JA, Omitowoju GO, et al. Intramuscular sulfadoxine-pyrimethamine in uncomplicated chloroquine-resistant falciparum malaria during pregnancy. Trans R Soc Trop Med Hyg 1993; 87: 472

    Article  PubMed  CAS  Google Scholar 

  89. Keuter M, van Eijk A, Hoogstrate M, et al. Comparison of chloroquine, pyrimethamine-sulfadoxine, and chlorproguanil and dapsone in pregnant and non-pregnant women, Kakamega district, Kenya. BMJ 1990; 301: 466–70 90. Schultz LJ, Steketee RW, Macheso A, et al. The efficacy of antimalarial regimens containing sulfadoxine-pyrimethamine and/or chloroquine in preventing peripheral and placental Plasmodium falciparum infection among pregnant women in Malawi. Am J Trop Med Hyg 1994; 51: 515–22

    Google Scholar 

  90. Steffen R, Fuchs E, Schildknecht J, et al. Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting East Africa. Lancet 1993; 341: 1299–303

    Article  PubMed  CAS  Google Scholar 

  91. Whalley PJ, Adams RH, Combes B. Tetracycline toxicity in pregnancy. JAMA 1964; 189: 357–62

    Article  PubMed  CAS  Google Scholar 

  92. Dowling HF, Lepper MH. Hepatic reactions to tetracycline. JAMA 1964; 188: 307–8

    Article  PubMed  CAS  Google Scholar 

  93. Kunelis CT, Peters JL, Edmondson HA. Fatty liver of pregnancy and its relationship to tetracycline therapy. Am J Med 1965; 38: 359–77

    Article  PubMed  CAS  Google Scholar 

  94. Riond J-L, Riviere JE. Pharmacology and toxicology of doxycycline. Vet Hum Toxicol 1988; 30: 431–43

    PubMed  CAS  Google Scholar 

  95. Looareesuwan S, Viravan C, Vanijanonta S, et al. Randomized trial of mefloquine-doxycycline, and artesunate-doxycycline for treatment of acute uncomplicated falciparum malaria. Am J Trop Med Hyg 1994; 50: 784–9

    PubMed  CAS  Google Scholar 

  96. Mvondo JL, James MA, Campbell CC. Malaria and pregnancy in Cameroonian women. Effect of pregnancy on Plasmodium falciparum parasitaemia and the response to chloroquine. Trop Med Parasitol 1992; 43: 1–5

    PubMed  CAS  Google Scholar 

  97. Schultz LJ, Steketee RW, Chitsulo L, et al. Malaria and childbearing women in Malawi: knowledge, attitudes and practices. Trop Med Parasitol 1994; 45: 65–9

    PubMed  CAS  Google Scholar 

  98. World Health Organization. The role of artemisinin and its derivatives in the current treatment of malaria (1994–1995). Geneva: World Health Organization, 1994. Report no. WHO/MAL/94.1067

  99. Severe anaemia in pregnancy: a problem of primigravidae in rural Zaire. Trans R Soc Trop Med Hyg 1991; 85: 829–32

    Article  Google Scholar 

  100. Greenwood AM, Menendez C, Alonso PL, et al. Can malaria chemoprophylaxis be restricted to first pregnancies? Trans R Soc Trop Med Hyg 1994; 88: 681–2

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Malaria Unit, Division of Control of Tropical Diseases, World Health Organization, Switzerland

    Penelope A. Phillips-Howard & Dawn Wood

  2. Kenya Medical Research Institute, PO Box 1578, Kisumu, Kenya

    Penelope A. Phillips-Howard

Authors
  1. Penelope A. Phillips-Howard
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dawn Wood
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Phillips-Howard, P.A., Wood, D. The Safety of Antimalarial Drugs in Pregnancy. Drug-Safety 14, 131–145 (1996). https://doi.org/10.2165/00002018-199614030-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199614030-00001

Keywords

Search

Navigation